Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 5/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR5A | P47898 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6200041 | 1.00 | TOP1 (0.39) | TOP1PARP1HTR1AHTR1DSLC6A4 | |
| Hydrochloric Acid SCHEMBL7235176 | 0.99 | TOP1 (0.39) | TOP1PARP1HTR1AHTR1DSLC6A4 | |
| Hydrochloric Acid SCHEMBL7235171 | 0.99 | TOP1 (0.39) | TOP1PARP1HTR1AHTR1DSLC6A4 | |
| Hydrochloric Acid SCHEMBL7226289 | 0.93 | TOP1 (0.34) | TOP1PARP1MAOA | |
| Hydrochloric Acid SCHEMBL7226286 | 0.93 | TOP1 (0.34) | TOP1PARP1MAOA | |
| Hydrochloric Acid SCHEMBL7246732 | 0.92 | POLB (0.35) | TOP1PARP1 | |
| Hydrochloric Acid SCHEMBL7246736 | 0.92 | POLB (0.35) | TOP1PARP1 | |
| Hydrochloric Acid SCHEMBL7227764 | 0.90 | TOP1 (0.36) | TOP1PARP1HTR1AHTR1DSLC6A4 | |
| Hydrochloric Acid SCHEMBL7227762 | 0.90 | TOP1 (0.36) | TOP1PARP1HTR1AHTR1DSLC6A4 | |
| Hydrochloric Acid SCHEMBL7226838 | 0.90 | TOP1 (0.33) | TOP1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1266887-B1 | Indenoindoline derivatives, their process of preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-08-17 | — | — | EP | claimed |
| US-6627650-B2 | An isomer thereof, or an addition salt thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful as anti- cancer agents. | LES LABORATOIRES SERVIER (FR) | 2003-09-30 | — | — | US | claimed |
| US-20030125369-A1 | Indeno(1,2-b)indole oximes or indeno(1,2-b) indole hydrazones used as anticancer agent | LES LABORATOIRES SERVIER (FR) | 2003-07-03 | — | — | US | claimed |
| US-6627650-B2 | An isomer thereof, or an addition salt thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful as anti- cancer agents. | LES LABORATOIRES SERVIER (FR) | 2003-09-30 | — | — | US | disclosed |
| US-20030125369-A1 | Indeno(1,2-b)indole oximes or indeno(1,2-b) indole hydrazones used as anticancer agent | LES LABORATOIRES SERVIER (FR) | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125369-A1 | Indeno(1,2-b)indole oximes or indeno(1,2-b) indole hydrazones used as anticancer agent | IDO1, IDO2, AHR | TOP1 104/4885PARP1 265/4885HTR1A 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.